## Abstract Previous studies provided a direct experimental evidence for the contribution of HCV core protein in the development of insulin resistance (IR), but the clinical impact of HCV core region on IR is still not clear. The present study evaluated the impact of Amino acid (aa) substitutions o
Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
β Scribed by Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 161 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
We showed previously that amino acid (aa) substitutions in hepatitis C virus core region (HCV-CR) are negative predictors of virologic response to pegylated interferon (IFN) plus ribavirin therapy. HCV-CR induces hepatocellular carcinoma in transgenic mice, but the clinical impact is still unclear. To evaluate the impact of aa substitutions in HCV-CR on hepatocarcinogenesis, we performed a follow-up study on 313 noncirrhotic consecutive naΓ―ve patients infected with HCV genotype 1b who received IFN monotherapy. The median follow-up was 14.7 years. A sustained virologic response (SVR) after the first IFN was achieved by 65 patients (20.8%) (group A). Of 248 patients (79.2%) of non-SVR after first IFN, 112 (35.8%) did not receive additional IFN (group B), and the remaining 136 (43.5%) received multicourse IFN monotherapy (group C). As a whole, cumulative hepatocarcinogenesis rates in double wild-type (arginine at aa 70/leucine at aa 91) of HCV-CR were significantly lower than those in nondouble wild-type. Multivariate analyses identified 3 parameters (fibrosis stage 3, nondouble wild-type of HCV-CR, and group B) that tended to or significantly influenced hepatocarcinogenesis independently. With regard to hepatocarcinogenesis rates in group C according to HCV-CR and the mean alanine aminotransferase (ALT) during IFN-free period, significantly higher rates were noted in patients of nondouble wild-type with ALT levels of more than 1.5 times the upper limit of normal (25.7%) compared with the others (2.4%).
Conclusion:
Amino acid substitutions in the hcv-cr are the important predictor of hepatocarcinogenesis. in multicourse ifn therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean alt during an ifn-free period below 1.5 times the upper limit of normal.
π SIMILAR VOLUMES
## Abstract Substitution of amino acid (aa) 70 and/or 91 in the core region of HCV genotype 1b (HCVβ1b) is an important predictor of hepatocarcinogenesis, but its impact on the development of hepatocellular carcinoma (HCC) following eradication of HCV RNA by antiviral therapy is not clear. 1,273 pa
## Abstract Previous studies identified amino acid (aa) substitutions of the hepatitis C virus core region of genotype 1b (HCVβ1b core region) and elevated serum alphaβfetoprotein (AFP) levels as predictors of poor virologic response to pegylated interferon (PEGβIFN) plus ribavirin (RBV), and also
Hepatitis C virus (HCV) load is one of the most important predictive factors of response to interferon treatment. However, little is known about the mode and determinants of viremia. The mode of viremia was investigated in 78 patients with chronic HCV genotype 1b infection during 1-2 years follow up
## Abstract It has been reported that genetic polymorphisms near the __IL28B__ gene or amino acid substitutions in hepatitis C virus (HCV) core protein are associated with the clinical outcome of peginterferon (PEGβIFN) and ribavirin combination therapy. The impact of these factors on the pure sens
## Abstract It is not known whether there is a trend of increasing or decreasing incidence of new hepatitis C virus (HCV) infections in Japan. From the treatment point of view, it is important to verify HCV genotypes and the prevalence of treatmentβresistant clones of HCV. At the Japanese Red Cross